A study was made of the effect of parathyroid hormone (PTH) on blood lead (7439921) concentrations in three situations without unusual lead exposures. Serum PTH levels were measured in 50 of 342 bus drivers, 23 with the highest blood lead levels and 24 with the lowest levels. Blood lead levels were measured in eight osteoporotic women before, after 3 weeks and after 1 year of therapy for bone building. Treatment included four 13 week cycles comprising 1 week of therapy with 400 units per day PTH fragment, calcitonin injections for the next 2 weeks and oral calcium supplements for the following 10 weeks. Lead levels were measured in a hyperparathyroid man, 66 years of age, in a 24 hour urine sample and in blood just before and daily for 5 days following chelation (done 2 weeks prior to parathyroidectomy). The same samples were taken 4 months after surgery. Mean blood lead levels in bus drivers were 12.0 and 3.3 micrograms/deciliter (microg/dl) in high and low lead groups, respectively. Mean PTH levels were 34.3 in both groups, and there were no significant differences in mean age, race or blood caffeine levels. Blood lead levels in women prior to bone building therapy ranged from 2.1 to 8.9, mean 6.0microg/dl. There was a mean decrease of 1.7microg/dl after 1 year, which was significantly different from levels before treatment or after 3 weeks. In the hyperparathyroid subject, blood lead was not affected by chelation but was decreased by 50% following parathyroidectomy. The author concludes that normal levels of PTH are unlikely to affect blood lead levels in environmentally exposed adults. Pathologic PTH elevations may increase blood lead by increasing bone activity or gastrointestinal absorption, and bone building therapies may decrease blood lead by decreased absorption or increased movement into bone.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.